Genomics and the impact of new technologies on the management of colorectal cancer.
High-throughput genomic technologies have the potential to have a major impact on preclinical and clinical drug development and the selection and stratification of patients in clinical trials. These technologies, which are at varying stages of commercialization, include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays, and (the most mature example) expression-based arrays. One of the rate-limiting steps in the routine clinical application of expression array-based technology is the need for suitable clinical samples. One of the major challenges moving forward, therefore, relates to the ability to use formalin-fixed, paraffin-embedded--derived tissue in expression profiling-based approaches.
Harkin
D Paul
DP
Queen's University, Belfast, Northern Ireland, United Kingdom. paul.harkin@arradx-almac.com
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015195:Drug Design; D005784:Gene Amplification; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D018390:Gene Targeting; D015894:Genome, Human; D023281:Genomics; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D016612:Paraffin Embedding
D000970:Antineoplastic Agents